275 related articles for article (PubMed ID: 29436940)
21. Giving Up on Precision Oncology? Not So Fast!
Warner JL
Clin Transl Sci; 2017 May; 10(3):128-129. PubMed ID: 28146309
[No Abstract] [Full Text] [Related]
22. Designing precision medicine trials to yield a greater population impact.
Zhao YQ; LeBlanc ML
Biometrics; 2020 Jun; 76(2):643-653. PubMed ID: 31598964
[TBL] [Abstract][Full Text] [Related]
23. Optimal decision-making in oncology development programs based on probability of success for phase III utilizing phase II/III data on response and overall survival.
Götte H; Xiong J; Kirchner M; Demirtas H; Kieser M
Pharm Stat; 2020 Nov; 19(6):861-881. PubMed ID: 32662598
[TBL] [Abstract][Full Text] [Related]
24. The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies.
Barry WT; Perou CM; Marcom PK; Carey LA; Ibrahim JG
J Biopharm Stat; 2015; 25(1):66-88. PubMed ID: 24836519
[TBL] [Abstract][Full Text] [Related]
25. Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics.
Scher HI; Nasso SF; Rubin EH; Simon R
Clin Cancer Res; 2011 Nov; 17(21):6634-40. PubMed ID: 22046024
[TBL] [Abstract][Full Text] [Related]
26. Is high-risk cutaneous squamous cell carcinoma of the head and neck a suitable candidate for current targeted therapies?
Zilberg C; Lee MW; Kraitsek S; Ashford B; Ranson M; Shannon K; Iyer NG; Ch'ng S; Low TH; Palme C; Clark J; Gupta R; Yu B
J Clin Pathol; 2020 Jan; 73(1):17-22. PubMed ID: 31300530
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials.
Claggett B; Pocock S; Wei LJ; Pfeffer MA; McMurray JJV; Solomon SD
Circulation; 2018 Aug; 138(6):570-577. PubMed ID: 29588314
[TBL] [Abstract][Full Text] [Related]
28. Subgroup identification for treatment selection in biomarker adaptive design.
Lu TP; Chen JJ
BMC Med Res Methodol; 2015 Dec; 15():105. PubMed ID: 26646831
[TBL] [Abstract][Full Text] [Related]
29. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
Horiguchi M; Hassett MJ; Uno H
Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
[TBL] [Abstract][Full Text] [Related]
30. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
Bozec A; Peyrade F; Milano G
Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
[TBL] [Abstract][Full Text] [Related]
31. Advancing cancer drug development through precision medicine and innovative designs.
Zhang W; Wang J; Menon S
J Biopharm Stat; 2018; 28(2):229-244. PubMed ID: 29173004
[TBL] [Abstract][Full Text] [Related]
32. Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints.
Mehta C; Schäfer H; Daniel H; Irle S
Stat Med; 2014 Nov; 33(26):4515-31. PubMed ID: 25130879
[TBL] [Abstract][Full Text] [Related]
33. Biomarker enrichment considerations in oncology early development single-arm studies.
Tian H; Liu K
J Biopharm Stat; 2018; 28(2):282-291. PubMed ID: 28934023
[TBL] [Abstract][Full Text] [Related]
34. Treatment evaluation for a data-driven subgroup in adaptive enrichment designs of clinical trials.
Zhang Z; Chen R; Soon G; Zhang H
Stat Med; 2018 Jan; 37(1):1-11. PubMed ID: 28948633
[TBL] [Abstract][Full Text] [Related]
35. Time-to-event analysis with treatment arm selection at interim.
Di Scala L; Glimm E
Stat Med; 2011 Nov; 30(26):3067-81. PubMed ID: 21898523
[TBL] [Abstract][Full Text] [Related]
36. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
37. Is EGFR really a therapeutic target in head and neck cancers?
Agarwal V; Subash A; Nayar RC; Rao V
J Surg Oncol; 2019 May; 119(6):685-686. PubMed ID: 30701564
[TBL] [Abstract][Full Text] [Related]
38. Assessing temporal agreement between central and local progression-free survival times.
Zeng D; Cornea E; Dong J; Pan J; Ibrahim JG
Stat Med; 2015 Feb; 34(5):844-58. PubMed ID: 25393731
[TBL] [Abstract][Full Text] [Related]
39. Two-stage approach based on zone and dose findings for two-agent combination Phase I/II trials.
Shimamura F; Hamada C; Matsui S; Hirakawa A
J Biopharm Stat; 2018; 28(6):1025-1037. PubMed ID: 29420127
[TBL] [Abstract][Full Text] [Related]
40. Two-stage designs for cross-over bioequivalence trials.
Kieser M; Rauch G
Stat Med; 2015 Jul; 34(16):2403-16. PubMed ID: 25809815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
